Literature DB >> 15229152

Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.

Julie A E Irving1, Stephen O'Brien, Anne L Lennard, Lynne Minto, Feng Lin, Andrew G Hall.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15229152     DOI： 10.1373/clinchem.2004.034801

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  3 in total

1.  Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and Monitoring.

Authors:  Nikolas von Bubnoff
Journal:  Ther Adv Hematol       Date:  2011-04

Review 2.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

3.  A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.

Authors:  Thomas Ernst; Franz X Gruber; Oliver Pelz-Ackermann; Jacqueline Maier; Markus Pfirrmann; Martin C Müller; Ingvild Mikkola; Kimmo Porkka; Dietger Niederwieser; Andreas Hochhaus; Thoralf Lange
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.